Trial Profile
A Phase 3, Randomized, Open-label Study of Subcutaneous and Intravenous VELCADE in Combination With Dexamethasone in Chinese Subjects With Relapsed or Refractory Multiple Myeloma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Nov 2019
Price :
$35
*
At a glance
- Drugs Bortezomib (Primary) ; Bortezomib (Primary) ; Dexamethasone
- Indications Multiple myeloma
- Focus Registrational; Therapeutic Use
- Sponsors Janssen Research & Development
- 13 Dec 2018 Status changed from active, no longer recruiting to completed.
- 01 May 2018 Planned End Date changed from 31 Dec 2018 to 10 Nov 2018.
- 01 May 2018 Planned primary completion date changed from 31 Dec 2018 to 9 Nov 2018.